Efruxifermin improves fibrosis in patients with metabolic dysfunction-associated steatohepatitis
1. Efruxifermin 50 mg once-weekly significantly improved fibrosis at 96 weeks versus placebo. 2. MASH resolution without worsened fibrosis was ...
1. Efruxifermin 50 mg once-weekly significantly improved fibrosis at 96 weeks versus placebo. 2. MASH resolution without worsened fibrosis was ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.